Shanhu Hu

Shanhu Hu has a diverse work experience in the field of pharmaceuticals and research. Starting in 2008 as a Research Assistant at the Institute of Neurology at Fudan University, Shanhu went on to work as a Graduate Researcher at the Geisel School of Medicine at Dartmouth. In this role, Shanhu focused on studying mechanisms of CDK2 inhibition in lung cancers and authored peer-reviewed publications.

In 2015, Shanhu joined Syros Pharmaceuticals as a Scientist and progressed to roles of increasing responsibility, including Senior Scientist, Principal Scientist, and Associate Director. At Syros Pharmaceuticals, Shanhu served as the project lead for an oncology preclinical project, successfully advancing the program from target validation to DC nomination.

Shanhu's most recent positions include Director at Exo Therapeutics, where they worked from 2022 to 2023, and Director, Head of HTS at Korro Bio, Inc., where they have been since 2023.

Shanhu Hu holds a Doctor of Philosophy (Ph.D.) degree in Pharmacology and Toxicology from the Geisel School of Medicine at Dartmouth. Prior to this, Shanhu Hu obtained a Bachelor's Degree in Biology/Biological Sciences from Fudan University.